Continuous infusions of lorazepam, midazolam, and propofol for sedation of the critically ill surgery trauma patient: A prospective, randomized comparison
- 1 November 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 27 (11) , 2454-2458
- https://doi.org/10.1097/00003246-199911000-00022
Abstract
To compare the efficacy, safety, and cost of continuous infusions of lorazepam, midazolam, and propofol in a critically ill trauma/surgery patient population. A prospective, randomized, nonblinded, single center. A 16-bed intensive care unit. A total of 30 ventilated patients who were 18-70 yrs of age and required pharmacologic sedation. Patients with renal and/or liver failure, a history of alcohol abuse, a head injury, or in a coma were excluded. Patients were randomized by block design to receive lorazepam, midazolam, or propofol. Initial boluses and infusion rates were as follows: lorazepam 0.05 mg/kg, then 0.007 mg/kg/hr; midazolam 0.05 mg/kg, then 0.003 mg/kg/hr; and propofol 0.25 mg/kg, then 0.06 mg/kg/hr. Sedation was assessed and agents titrated every 5-10 mins to achieve ≥2 and Maintenance doses of lorazepam 0.02 ± 0.01 mg/kg/hr, midazolam 0.04 ± 0.03 mg/kg/hr, and propofol 2.0 ± 1.5 mg/kg/hr achieved the desired level of sedation 68%, 79%, and 62% of the time, respectively. Oversedation occurred most often with lorazepam, compared with midazolam and propofol, at 14%, 6%, and 7% of the assessment times, respectively. Undersedation occurred most frequently with propofol compared with lorazepam and midazolam, at 31%, 18%, and 16% of the assessment times, respectively. The mean number of dosage changes per day was 7.8 ± 4.3 for lorazepam, 4.4 ± 2.9 for midazolam, and 5.6 ± 6.0 for propofol (p = .91). Sedation costs per patient day (mean ± SD) were $48 ± $76 (lorazepam), $182 ± $98 (midazolam), and $273 ± $200 (propofol) (p = .005). The potential savings, if all study patients had received lorazepam, is $14,208 compared with $8,808 if all received midazolam. The data suggest that lorazepam appears to be a cost-effective choice for sedation; however, oversedation may be problematic. Midazolam is the most titratable drug in our population, avoiding excessive oversedation or undersedation. Trauma patients may respond inadequately to propofol even at higher doses. Lorazepam may be the sedative of choice in critically ill trauma/surgery patients.Keywords
This publication has 15 references indexed in Scilit:
- Prolonged sedation of critically ill patients with midazolam or propofolCritical Care Medicine, 1997
- Comparative study of propofol versus midazolam in the sedation of critically ill patientsCritical Care Medicine, 1996
- Lorazepam Stability in Parenteral Solutions for Continuous Intravenous AdministrationAnnals of Pharmacotherapy, 1996
- Sedation of critically ill patients during mechanical ventilation. A comparison of propofol and midazolam.American Journal of Respiratory and Critical Care Medicine, 1996
- Sedation for the critically ill neurologic patientCritical Care Medicine, 1995
- Comparison of propofol and midazolam for sedation in intensive care unit patientsCritical Care Medicine, 1995
- Propofol vs Midazolam in Short-, Medium-, and Long-term Sedation of Critically III PatientsChest, 1993
- Use of Sedating Drugs and Neuromuscular Blocking Agents in Patients Requiring Mechanical Ventilation for Respiratory FailurePublished by American Medical Association (AMA) ,1991
- Midazolam: The First Water‐soluble Benzodiazepine; Pharmacology, Pharmacokinetics and Efficacy in Insomnia and AnesthesiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1985
- PROLONGED INFUSION OF CHLORMETHIAZOLE IN INTENSIVE CAREBritish Journal of Anaesthesia, 1980